Revance Therapeutics (RVNC) 13.25 $RVNC Shareholder

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Revance Therapeutics (RVNC) 13.25 $RVNC

Shareholder Alert: Sohmer Law Firm Investigating Revance Therapeutics, Inc.
BusinessWire - Mon Jul 25, 9:46AM CDT
The Sohmer Law Firm announces that it is investigating possible breaches of fiduciary duty claims by the board of directors of Revance Therapeutics, Inc. (NASDAQ:RVNC).
RVNC: 13.25 (-0.24)

Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.19 (+0.09), MPAA: 28.24 (+0.21), NAV: 12.72 (-0.10), RVNC: 13.25 (-0.24), WFC: 47.81 (-0.16), SYF: 27.91 (+0.03), MSB: 9.40 (-0.97)

Why is Revance Therapeutics (RVNC) Stock Plummeting Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 14, 10:48AM CDT
On Tuesday, shares of Revance Therapeutics Inc. (RVNC) are plummeting, down over 22% in morning trading after the company reported disappointing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.25 (-0.24)

Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), RVNC: 13.25 (-0.24), BMY: 76.19 (+1.38)

Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
GlobeNewswire - Mon Jun 13, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe lateral canthal lines, or crow's feet.
RVNC: 13.25 (-0.24)

Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
GlobeNewswire - Thu Jun 02, 5:12PM CDT
- Portfolio covers diverse and novel indications, compositions and formulations -
RVNC: 13.25 (-0.24)

Revance to Participate in Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences.
RVNC: 13.25 (-0.24)

Revance reports 1Q loss
Automated Insights - Mon May 09, 5:48PM CDT
NEWARK, Calif. (AP) _ Revance Therapeutics Inc. (RVNC) on Monday reported a loss of $19.9 million in its first quarter.
RVNC: 13.25 (-0.24)

Revance Releases First Quarter 2016 Results
GlobeNewswire - Mon May 09, 3:06PM CDT
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -
RVNC: 13.25 (-0.24)

Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
GlobeNewswire - Mon Apr 25, 3:01PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.
RVNC: 13.25 (-0.24)

Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development
GlobeNewswire - Mon Mar 14, 6:17PM CDT
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced a key addition to its leadership team with the appointment of Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development, effective immediately. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company's clinical development team, focusing on further accelerating the advancement of Revance's neurotoxin development programs.
RVNC: 13.25 (-0.24)

Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology
GlobeNewswire - Sat Mar 05, 12:45PM CST
- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX(R) Cosmetic -
RVNC: 13.25 (-0.24)

Axillary Hyperhidrosis Pipeline Review H2 2015
M2 - Tue Feb 02, 5:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/w8hlmc/axillary) has announced the addition of the "Axillary Hyperhidrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Axillary Hyperhidrosis Overview - Therapeutics Development - Pipeline Products for Axillary Hyperhidrosis - Overview - Pipeline Products for Axillary Hyperhidrosis - Comparative Analysis - Axillary Hyperhidrosis - Therapeutics under Development by Companies - Axillary Hyperhidrosis - Therapeutics under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Axillary Hyperhidrosis - Products under Development by Companies - Axillary Hyperhidrosis - Products under Investigation by Universities/Institutes - Axillary Hyperhidrosis - Companies Involved in Therapeutics Development - Allergan Plc - Brickell Biotech, Inc. - Dermira Inc. - GlaxoSmithKline Plc - Revance Therapeutics, Inc. - TheraVida, Inc For more information visit http://www.researchandmarkets.com/research/w8hlmc/axillary
AGN: 254.86 (+1.91), DERM: 33.20 (-0.36), RVNC: 13.25 (-0.24), GSK: 45.25 (+0.18)

Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.41 (-0.14), TRVN: 6.39 (+0.12), VRTX: 98.20 (+1.20), RDHL: 14.55 (+1.42), ZSAN: 1.40 (-0.35), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), ACOR: 25.13 (-0.15), NKTR: 17.76 (+0.47), AGN: 254.86 (+1.91), CORI: 4.73 (-0.05), ALDR: 30.79 (-1.31), CLCD: 8.63 (-0.07), MRK: 58.66 (unch), TEVA: 53.61 (+0.11), RVNC: 13.25 (-0.24), POZN: 5.94 (-0.43)

The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:30AM CST
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and Exelixis
LGND: 138.53 (+3.65), AMGN: 174.16 (+2.13), RVNC: 13.25 (-0.24), ABBV: 66.94 (+0.71), EXEL: 9.27 (+0.09)

5 Biotech Stocks That Doubled in 2015
Arpita Dutt - Zacks Investment Research - Thu Jan 07, 11:17AM CST
Here is a look at 5 biotech stocks that doubled in 2015 despite the volatility in the sector.
HRTX: 16.90 (+0.28), SRPT: 25.91 (+0.63), LGND: 138.53 (+3.65), AMGN: 174.16 (+2.13), RVNC: 13.25 (-0.24), ABBV: 66.94 (+0.71), EXEL: 9.27 (+0.09)

Dystonia therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/kz7qhs/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dystonia Overview - Therapeutics Development - Pipeline Products for Dystonia - Overview - Pipeline Products for Dystonia - Comparative Analysis - Dystonia - Therapeutics under Development by Companies - Dystonia - Therapeutics under Investigation by Universities/Institutes - Dystonia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dystonia - Products under Development by Companies - Dystonia - Products under Investigation by Universities/Institutes - Dystonia - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - Advicenne Pharma - EpiVax, Inc. - Ipsen S.A. - Revance Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kz7qhs/dystonia
RVNC: 13.25 (-0.24)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 78

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 54

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 27

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 107

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 190

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 64

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 119

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 152

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 41

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading

Top 5 Most Recently Viewed Articles

Legacy of Lovers Unveils Transformative Single Addition

Updated Category News Views 154

Legacy of Lovers Launches New Musical Journey with 'Calm Cool Connection' With an exciting new release, Endless Love embraces the future of music with their single 'Calm Cool Connection'. This dynamic piece captures the essence of personal transformation and encourages listeners to embrace their own journeys. The track stands out, infused with bright melodies and...

Continue Reading
Major Shareholding Update for Park Street A/S Shareholders

Updated Category News Views 162

Significant Shareholding Announcement Park Street A/S is making headlines with its recent announcement regarding major shareholder developments. The company, a key player in its industry, has disclosed essential updates about the share capital and voting rights held by Park Street Asset Management Ltd., a trusted partner in managing its shareholding. Capital Reduction and...

Continue Reading
Alamos Gold's Robust Quarterly Dividend and Strategic Buybacks

Updated Category News Views 150

Quarterly Dividend Announcement by Alamos Gold All figures mentioned are in United States dollars unless specified otherwise. In a recent announcement, Alamos Gold Inc. (TSX:AGI; NYSE:AGI) has revealed a significant update regarding its shareholder value strategies. The Company’s Board of Directors has declared a quarterly dividend of US$0.025 per common share. This...

Continue Reading
AITX Expands Innovative Logistics Solutions with ROAMEO

Updated Category News Views 98

Revolutionizing Logistics with AITX and ROAMEO In an ever-changing world of logistics, AITX’s Robotic Assistance Devices, Inc. (RAD) is stepping up to the plate with new solutions that elevate operational efficiency and security standards. The company has honed its focus on creating tailored solutions for the logistics sector, which is widely acknowledged for its...

Continue Reading
BlackRock's Bold Bet on Bitcoin Amid Microsoft's Hesitation

Updated Category News Views 131

BlackRock's Investment Insights Into Bitcoin Microsoft Corp. (NASDAQ: MSFT) recently made headlines when it decided against exploring Bitcoin as a potential investment. Despite this, its significant shareholder, BlackRock, is making waves with its strong backing for the leading cryptocurrency. Known for its strategic investments, BlackRock's optimism presents a stark...

Continue Reading